AMAM Insider Trading Activity and SEC Form 4 Filings
AMAM insider trading summary
No open-market insider purchases or sales of Ambrx Biopharma, Inc. (AMAM) have been reported on SEC Form 4 in the past 12 months.
Latest AMAM insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 27, 2023 | Daniel J. O'Connor | President and CEO | Sell | $491K (50,012 @ $9.82) |
| Oct 27, 2023 | Sonja Nelson | Chief Financial Officer | Sell | $125K (12,778 @ $9.82) |
| Oct 23, 2023 | Cormorant Global Healthcare Master Fund, LP | Insider | Buy | $9.1M (1,307,311 @ $6.99) |
| Oct 23, 2023 | Bihua Chen | Insider | Buy | $9.1M (1,307,311 @ $6.99) |
| Oct 23, 2023 | Cormorant Asset Management, LP | Insider | Buy | $9.1M (1,307,311 @ $6.99) |
| Oct 23, 2023 | Cormorant Private Healthcare Fund III LP | Insider | Buy | $9.1M (1,307,311 @ $6.99) |
| Sep 18, 2023 | Cormorant Asset Management, LP | Insider | Buy | $6.9M (751,233 @ $9.24) |
| Sep 18, 2023 | Cormorant Global Healthcare Master Fund, LP | Insider | Buy | $6.9M (751,233 @ $9.24) |
| Sep 18, 2023 | Bihua Chen | Insider | Buy | $6.9M (751,233 @ $9.24) |
| Sep 18, 2023 | Cormorant Private Healthcare Fund III LP | Insider | Buy | $6.9M (751,233 @ $9.24) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.